Search

Your search keyword '"Dennis Kannenkeril"' showing total 87 results

Search Constraints

Start Over You searched for: Author "Dennis Kannenkeril" Remove constraint Author: "Dennis Kannenkeril"
87 results on '"Dennis Kannenkeril"'

Search Results

1. Is GFR decline induced by SGLT2 inhibitor of clinical importance?

2. Sodium quantification in skeletal muscle: comparison between Cartesian gradient-echo and radial ultra-short echo time 23Na MRI techniques

3. Determinants of arterial stiffness in patients with type 2 diabetes mellitus: a cross sectional analysis

4. Angiotensin pathways under therapy with empagliflozin in patients with chronic heart failure

5. Is vascular remodelling in patients with chronic heart failure exaggerated?

6. Change of renal function after short-term use of cardioprotective agents in patients with type 2 diabetes is not accurately assessed by the change of estimated glomerular filtration rate: an observational study

7. Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers

8. Effects of the sodium‐glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure

9. Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine

10. Renal and intraglomerular haemodynamics in chronic heart failure with preserved and reduced ejection fraction

11. Association of Noise Annoyance with Measured Renal Hemodynamic Changes

12. Microvascular changes at different stages of chronic kidney disease

13. Supine blood pressure—A clinically relevant determinant of vascular target organ damage in hypertensive patients

14. How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial

15. 4.6 Effects of Combined Therapy of Empagliflozin and Linagliptin Versus Metformin and Insulin Glargine on Blood Pressure and Vascular Function in Patients with Type 2 Diabetes

16. Early vascular parameters in the micro- and macrocirculation in type 2 diabetes

17. Retinal vascular resistance in arterial hypertension

18. P142 EARLY VASCULAR PARAMETERS IN THE MICRO- AND MACROCIRCULATION IN TYPE 2 DIABETES

19. 5.1 EFFECTS OF THE SGLT-2 INHIBITOR EMPAGLIFLOZIN ON VASCULAR FUNCTION AND CENTRAL HEMODYNAMICS IN PATIENTS WITH TYPE 2 DIABETES

20. The SGLT2 inhibitor empagliflozin reduces tissue sodium content in patients with chronic heart failure: results from a placebo-controlled randomised trial

21. Is vascular remodelling in patients with chronic heart failure exaggerated?

22. Retinal Capillary Damage Is Already Evident in Patients With Hypertension and Prediabetes and Associated With HbA1c Levels in the Nondiabetic Range

23. Simultaneously measured inter-arm blood pressure difference is not associated with pulse wave velocity in a clinical dataset of at-risk hypertensive patients

24. Role of Microparticles in Cardiovascular Disease: Implications for Endothelial Dysfunction, Thrombosis, and Inflammation

25. Capillary vascular density in the retina of hypertensive patients is associated with a non-dipping pattern independent of mean ambulatory blood pressure

26. Increased pulse wave velocity in patients with an orthostatic blood pressure rise independent of other cardiovascular risk factors

27. Detection of Changes in Renal Blood Flow Using Arterial Spin Labeling MRI

28. Microvascular changes at different stages of chronic kidney disease

29. Retinal neurodegeneration in patients with end-stage renal disease assessed by spectral-domain optical coherence tomography

32. Reduced tissue sodium content is related to improvement of vascular function in patients with chronic heart failure treated with the SGLT2 inhibitor empagliflozin

34. Combination of empagliflozin and linagliptin improves blood pressure and vascular function in type 2 diabetes

35. Evidence of neurodegeneration in individuals with only mildly elevated blood pressure

36. Tissue sodium content in patients with type 2 diabetes mellitus

37. Simultaneously measured inter-arm blood pressure difference is not associated with pulse wave velocity in a clinical dataset of at-risk hypertensive patients

38. Dependency of flow-mediated vasodilatation from basal nitric oxide activity

39. Tissue sodium content correlates with hypertrophic vascular remodeling in type 2 diabetes

40. Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure

44. Capillary vascular density in the retina of hypertensive subjects is associated with a non-dipping pattern independent of mean ambulatory blood pressure

45. Abstract 12895: Tissue Sodium Content Increases With Severity of Chronic Heart Failure

46. Abstract 12882: Renal Hemodynamics in Chronic Heart Failure With Preserved and Reduced Ejection Fraction

47. Supine blood pressure-A clinically relevant determinant of vascular target organ damage in hypertensive patients

48. The influence of aircraft noise exposure on the systemic and renal haemodynamics

49. Validation of semi-automated flow-mediated dilation measurement in healthy volunteers

50. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial

Catalog

Books, media, physical & digital resources